← Back to Screener
Sionna Therapeutics, Inc. Common Stock (SION)
Price$40.90
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-5.97%
Price vs S&P 500 (4W)4.40%
VGM Score74.19
Market Capitalization$1.93B
All Metrics
Book Value / Share (Quarterly)$6.39
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.60
Price vs S&P 500 (YTD)-6.85%
EPS (TTM)$-1.92
10-Day Avg Trading Volume0.32M
EPS Excl Extra (TTM)$-1.92
EPS (Annual)$-1.88
ROI (Annual)-24.53%
Cash / Share (Quarterly)$4.80
ROA (Last FY)-23.09%
EBITD / Share (TTM)$-2.21
Cash Flow / Share (Annual)$-1.49
P/B Ratio6.71x
P/B Ratio (Quarterly)6.26x
Net Income / Employee (Annual)$-1,275,700
ROA (TTM)-25.88%
EPS Incl Extra (Annual)$-1.88
Current Ratio (Annual)20.61x
Quick Ratio (Quarterly)22.11x
3-Month Avg Trading Volume0.35M
52-Week Price Return203.47%
Revenue / Employee (TTM)$0
52-Week High$48.45
EPS Excl Extra (Annual)$-1.88
26-Week Price Return9.96%
Quick Ratio (Annual)20.14x
13-Week Price Return12.68%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)22.60x
Enterprise Value$1.87B
Revenue / Employee (Annual)$0
Cash / Share (Annual)$5.27
3-Month Return Std Dev67.57%
Net Income / Employee (TTM)$-1,450,300
ROE (Last FY)-24.53%
EPS Basic Excl Extra (Annual)$-1.88
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.92
ROI (TTM)-27.31%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)175.27%
Year-to-Date Return4.08%
5-Day Price Return4.11%
EPS Normalized (Annual)$-1.88
Month-to-Date Return10.65%
EBITD / Share (Annual)$-2.21
EPS Basic Excl Extra (TTM)$-1.92
P/B Ratio (Annual)5.98x
Book Value / Share (Annual)$6.86
Price vs S&P 500 (13W)2.94%
Beta2.05x
Revenue / Share (TTM)$0.00
ROE (TTM)-27.31%
52-Week Low$12.71
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.60est. -0.52
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.21
4.19
4.19
4.19
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SIONSionna Therapeutics, Inc. Common Stock | — | — | B | $40.90 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Sionna Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for cystic fibrosis (CF), a progressive genetic disorder caused by mutations in the CFTR gene. The company's approach targets the disease mechanism by normalizing CFTR protein function to deliver clinically meaningful benefits. The company is entirely focused on CF drug development.